Table 3:
Baseline clinical and demographic variables in episodic migraine patients by treatment responder status
| Variable | Treatment Responder | p valuea | |
|---|---|---|---|
| Yes (n=37) | No (n=58) | ||
| Sex (%) | |||
| Male | 2 (5.41) | 6 (10.34) | 0.48 |
| Female | 35 (94.59) | 52 (89.66) | |
| Age/median (range) | 35 (22–65) | 37 (18–63) | 0.77 |
| Race/n (%) | |||
| Black | 22 (59.46) | 47 (81.03) | 0.06 |
| White | 8 (21.62) | 8 (13.79) | |
| Other | 6 (16.22) | 3 (5.17) | |
| Unknown | 1 (2.7) | 0 | |
| Education/ n (%) | |||
| Some College or Less | 11 (29.73) | 8 (13.79) | 0.06 |
| College and Above | 26 (70.27) | 50 (86.21) | |
| BMI/median (range) | 28.64 (16.75–47.44) | 25.03 (15.66–45.45) | 0.05 |
| Migraine Qualities at Baseline | |||
| Low Frequency (4–8 days)/n (%) | 16 (43.24) | 32 (55.17) | 0.26 |
| High Frequency (9–14 days)/n (%) | 21 (56.76) | 26 (44.83) | |
| Headache Days/median (range) | 9 (5–13) | 8 (3–14) | 0.15 |
| Baseline Headache Pain/mean±SD | 4.74±1.38 | 4.35±1.59 | 0.22 |
| HIT-6 Total mean±SD | 60.59± 5.86 | 61± 5.40 | 0.73 |
| Idiopathic Pain/n (%) | |||
| Yes | 15 (40.54) | 12 (20.69) | 0.04 |
| No | 22 (59.46) | 46 (79.31) | |
| Preventative Migraine Medication Use b /n (%) | |||
| Yes | 8 (21.62) | 6 (10.34) | 0.13 |
| No | 29 (73.38) | 52 (89.66) | |
| Sleep quality and psychosocial measures/ Median (range) | |||
| PSQI | 4.67 (1.17–11.67) | 3.5 (0–14) | 0.07 |
| GAD-7 | 1 (0–16) | 1 (0–16) | 0.63 |
| PHQ-9 | 3 (0–13) | 2 (0–10) | 0.38 |
| PSS | 12 (2–28) | 11.5 (1–32) | 0.28 |
Abbreviations: HIT-6: headache impact test, PSS: perceived stress score, GAD-7: generalized anxiety disorder, PHQ-9: patient healthy questionnaire, PSQI: Pittsburgh sleep quality index
a
p values calculated from T tests, Chi Square, Wilcoxon, Kruskal Wallis tests.
b
Preventative medications cover four categories of medications which have been combined in this table.
c
Psychological medication covered three categories, which have been combined in this table.